Strides and Kenox partner to expand US nasal spray portfolio

Strides Pharma Science, through its wholly-owned subsidiary Strides Pharma Global Pte. Limited, Singapore, has entered into a strategic product development partnership with Kenox Pharmaceuticals Inc. This collaboration, announced on September 8, 2025, aims to expand Strides' nasal spray portfolio for the US market across diverse therapeutic indications.

Under the agreement, Kenox will provide formulation and development expertise for orally inhaled and nasal drug products (OINDPs). The partnership is expected to accelerate the availability of affordable, high-quality medicines for US patients by combining Strides' commercial strengths with Kenox's specialized OINDP expertise. Specific product details remain confidential.

Aditya Kumar, executive director business development at Strides Pharma Science Limited, highlighted that nasal sprays are a key focus area and that this collaboration builds on existing progress, leveraging investments in US facilities. Dr. Sitaram Velaga, founder, president and chief executive officer of Kenox Pharmaceuticals Inc., noted that the partnership validates Kenox's OINDP expertise and will enable the company to bring drug products to a global patient base at an affordable price.